1-(4-Amino-2-methylbenzoyl)-7-chloro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one NEW

$0.00 1kg

$0.00 5kg

$0.00 25kg

Min. Order1kg
Purity99.0%
Cas No137977-97-0
Supply Ability5000
Update time2024-11-25

Enki Biopharmaceuticals (Shanghai) Limited

2YR

China

Since2014-09-10

AddressRoom 708, Building B(No. 2), No.125 Laiting South Road, Songjiang District, Shanghai,China

show less show more

Chemical Properties

Product Name	1-(4-Amino-2-methylbenzoyl)-7-chloro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-one
CAS No	137977-97-0
EC-No
Min. Order	1kg
Purity	99.0%
Supply Ability	5000
Release date	2024/11/25

Enki Biopharma initiated the research and development of 'Tolvaptan' in 2009, which has become our most advantageous product. Over the past decade, we have established a series of production chains from the main ring (CAS No.:160129-45-3) to the raw material of Tolvaptan. The annual production capacity of Tolvaptan's main ring is nearly 2 tons, while that of its N-2 intermediate (CAS No.:137977-97-0) is close to 800 kilograms, and the overall production volume of Tolvaptan is around one hundred kilograms. The manufacturing facilities for both Tolvaptan's main ring and N-2 intermediate have undergone audits by numerous domestic and international pharmaceutical companies. Additionally, CMC files can be provided for Tolvaptan's N-2 intermediate."

show less show more

Company Profile Introduction

Enki Biopharmaceuticals (shanghai) Limited. is a cutting-edge pharmaceutical company committed to the comprehensive exploration, development, manufacturing, and commercialization of top-tier pharmaceutical products. The company established its state-of-the-art technology research and development center in Suzhou City, Jiangsu Province in 2016 and possesses production facilities located in Sichuan Province and Hunan Province. Enki Biopharma is propelled by technological research and development, with a primary focus on the R&D and production of high value-added and high-tech pharmaceutical intermediates/chiral compounds. The ultimate objective is to achieve industrialization through the creation of active pharmaceutical ingredients (APIs), while concurrently establishing core competencies in chiral synthesis, chemical/enzymatic catalysis, and clean production processes. The products primarily target premium foreign markets while simultaneously serving as intermediate support for domestic API production. Enki Biopharma embraces a market-oriented business philosophy, with innovation support and industrialization as its ultimate goals. It upholds the corporate spirit of focus, expertise, innovation, and win-win situations while remaining committed to the mission of creating value for customers, providing opportunities for employees, and promoting human health. Our utmost dedication lies in delivering high-quality products and premium services to our esteemed customers in order to achieve mutual success together. Simultaneously, we strive to foster employee development and promote social harmony.